A comparison of FLT to FDG PET/CT in the early assessment of chemotherapy response in stages IB–IIIA resectable NSCLC
Molecular Targeted Therapy
Poly(ADP-ribose) Polymerase Inhibitors
Small Cell Lung Carcinoma
Xenograft Model Antitumor Assays
Fractional decrease in FDG SULmax from baseline to post-cycle 1 imaging was significantly different between anatomic responders and non-responders, while percentage changes in FLT SULmax were not significantly different between these groups over the same period of time.